Filing Flows › ImmunityBio (IBRX) › Q2 2026 › vs Q2 2025
ImmunityBio (IBRX) Q2 2026 vs Q2 2025 (year over year)
ImmunityBio's revenue rose $24.8M (+94%) from $26.4M in Q2 2025 to $51.2M in Q2 2026. The biggest changes: Product revenue, net +$24.3M (+92%); Other revenues +$564K (142×).
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $50.7M | $26.4M | $24.3M | +92% |
| Other revenues | $568K | $4K | $564K | 142× |
| Revenue | $51.2M | $26.4M | $24.8M | +94% |
| Net loss | $230M | $92.6M | $138M | +149% |
| Costs & expenses | $282M | $119M | $163M | +137% |
| Operating costs | $113M | $97.7M | $15.2M | +16% |
| Interest & other, net | $169M | $21.0M | $148M | +703% |
| Cost of revenue | $298K | $136K | $162K | +119% |
| Other operating costs | $113M | $97.6M | $15.1M | +15% |
| Operating cash sources | $230M | $92.6M | $138M | +149% |
| Depreciation & amortization | $4.4M | $3.9M | $527K | +14% |
| Share-based compensation | $8.5M | $9.6M | −$1.1M | -12% |
| Working capital & other | $151M | −$700K | $152M | — |
| Cash used in operations | $66.5M | $79.7M | −$13.3M | -17% |
| Net loss absorbed | $230M | $92.6M | $138M | +149% |
Questions
How much did ImmunityBio's revenue grow year over year in Q2 2026?
ImmunityBio's revenue rose $24.8M (+94%) from $26.4M in Q2 2025 to $51.2M in Q2 2026.
What drove ImmunityBio's revenue change in Q2 2026?
Product revenue, net +$24.3M (+92%); Other revenues +$564K (142×).